Back to Search Start Over

More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study.

Authors :
Monari C
Sagnelli C
Maggi P
Sangiovanni V
Numis FG
Gentile I
Masullo A
Rescigno C
Calabria G
Megna AS
Gambardella M
Manzillo E
Russo G
Esposito V
Camaioni C
Messina V
Pisaturo M
Allegorico E
Pinchera B
Pisapia R
Catalano M
Salzillo A
Porta G
Signoriello G
Coppola N
Source :
Frontiers in oncology [Front Oncol] 2021 May 07; Vol. 11, pp. 662746. Date of Electronic Publication: 2021 May 07 (Print Publication: 2021).
Publication Year :
2021

Abstract

Background: The aim of the study was to compare coronavirus disease 2019 (COVID-19) severity presentation between oncologic and non-oncologic patients and to evaluate the impact of cancer type and stage on COVID-19 course.<br />Methods: We performed a multicentre, retrospective study involving 13 COVID-19 Units in Campania region from February to May 2020. We defined as severe COVID-19 presentation the cases that required mechanical ventilation and/or admission to Intensive Care Units (ICU) and/or in case of death.<br />Results: We enrolled 371 COVID-19 patients, of whom 34 (9.2%) had a history or a diagnosis of cancer (24 solid, 6 onco-hematological). Oncologic patients were older (p<0.001), had more comorbidities (p<0.001) and showed a higher rate of severe COVID-19 presentation (p=0.001) and of death (p<0.001). Compared to 12 patients with non-active cancer and to 337 without cancer, the 17 patients with active cancer had more comorbidities and showed a higher rate of severe COVID-19 and of mortality (all p values <0.001). Compared to the 281 non-severe patients, the 90 subjects with a severe presentation of COVID-19 were older (p<0.01), with more comorbidities (p<0.001) and with a higher rate of cancer (p=0.001). At multivariate analysis, age (OR 1.08, 95% CI: 1.04-1.11) and suffering from cancer in an active stage (OR 5.33, 95% CI: 1.77-16.53) were independently associated with severe COVID-19.<br />Conclusions: Since the higher risk of severe evolution of COVID-19, cancer patients, especially those with an active malignancy, should be candidates for early evaluation of symptoms and early treatment for COVID-19.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Monari, Sagnelli, Maggi, Sangiovanni, Numis, Gentile, Masullo, Rescigno, Calabria, Megna, Gambardella, Manzillo, Russo, Esposito, Camaioni, Messina, Pisaturo, Allegorico, Pinchera, Pisapia, Catalano, Salzillo, Porta, Signoriello and Coppola.)

Details

Language :
English
ISSN :
2234-943X
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
34026639
Full Text :
https://doi.org/10.3389/fonc.2021.662746